1. OPTN region (if applicable)
01 02 03 04 05 06 07 08 09 10 11
https://optn.transplant.hrsa.gov/about/regions/
2. Country
* must provide value
Afghanistan Albania Algeria Andorra Angola Antigua & Deps Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia Herzegovina Botswana Brazil Brunei Bulgaria Burkina Burundi Cambodia Cameroon Canada Cape Verde Central African Rep Chad Chile China Colombia Comoros Congo Congo {Democratic Rep} Costa Rica Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Indonesia Iran Iraq Ireland {Republic} Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea North Korea South Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Romania Russian Federation Rwanda St Kitts & Nevis St Lucia Saint Vincent & the Grenadines Samoa San Marino Sao Tome & Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad & Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe Other
4. The person responding to this survey is
Surgeon
Anesthesiologist
Critical Care physician
Neurologist
Different subspeciality
4d. Please specify your specialty
5. How many procurements of DCD liver donors approximately are performed in your institution yearly?
* must provide value
0-10
10-20
20-50
50-100
100-200
6. What is your center's upper age limit for a DCD hepatic donor in your center?
* must provide value
50 years
60 years
Other
We do not have an upper age limit for DCD liver
6d. Please specify the other age limit
7. What is your center's upper BMI limit for a DCD hepatic donor?
* must provide value
Below 30 kg/m2
Below 45 kg/m2
We do not have a BMI limit
Other BMI limit
7d. Please specify the other BMI limit
8. Where does the withdrawal of life support treatment in DCD liver donors take place?
* must provide value
In the Operating Room
In the Intensive Care Unit
Both locations: Operating Rooms and Intensive Care Units
Other locations
8d. Please describe the other locations
9. Based on OPTN definition, the Agonal stage for the potential donor DCD older than 11 years old is described as systolic blood pressure less than 80 mmHg, or oxygen saturation is less than 80%, sustained for at least 5 minutes. If your institution uses different criteria for the comparable stage associated with significant hemodynamic and/or oxygenation deterioration, please describe it in the text field. At your institution:
* must provide value
a. The Agonal (or comparable) stage starts with a drop of oxygen saturation below 80% only. b. The Agonal (or comparable) stage starts with a drop of systolic blood pressure below 80 mmHg only. c. The Agonal (or comparable) stage starts with a combination of a and b only. d. Other approach or other criteria for the Agonal or comparable stage (please describe)
9d. Other approach or other criteria for the Agonal or comparable stage (please describe)
10a. Based on OPTN criteria, circulatory death is defined as the irreversible cessation of circulatory functions. Death is declared in accordance with hospital policy and applicable state and local statutes and regulations Please briefly describe your center's protocol for death declaration
10b. Please attach your center's protocol for death declaration if available
11. For the purpose of this study only, we defined "Preliminary Warm Ischemic Time (pWIT)" as a time necessary for decision-making for acceptance or not acceptance of the patient as a potential DCD donor. This time can be generally assessed between these two-time points:
life support withdrawal and patient death start of agonal phase and patient death At your institution, pWIT for DCD liver donors is based on the duration of the period between these two-time points :
* must provide value
a. Between life support withdrawal and patient death b. Between the starting of the Agonal stage (or comparable stage at your institution/country) and patient death c. At our Institution, we use different approach (please describe)
11c. At our Institution, we use different approach (please describe)
12. The maximal duration of pWIT for DCD liver donors at your institution is:
* must provide value
30 min
60 min
90 min
Other duration (please describe)
12d. Other duration (please describe)
13. What do you think is the maximal acceptable duration of pWIT for DCD liver donors:
* must provide value
30 min
60 min
90 min
Other duration
14. At your institution during DCD liver grafts procurement, how often are sedative medication(s) used for patient comfort after life support withdrawal?
* must provide value
Never
< 50%
≥50% but not for all
For all
14a. Please briefly describe your sedation protocol (type of medication/s and dose)
14b. Please attach your sedation protocol if available
14c. please describe briefly your criteria for usage of these medications
15. At your institution during DCD liver grafts procurement, heparin administration is performed:
* must provide value
Before death declaration
After death declaration
Heparin is not used
15a. If heparin is used, please describe the dose
16. In your institution during DCD liver grafts procurement, the donor cannulation for the normothermic regional perfusion (NRP) is performed
* must provide value
Before death declaration
After death declaration
NRP is not performed at our institution
17. Who makes a decision regarding the stopping of the waiting time and acceptance of the patients as potential DCD hepatic donors or return to the ICU?
* must provide value
17e. Please specify other decision-makers
18. Do you use machine perfusion (ex-situ or in-situ) for DCD hepatic grafts at your institution, and if yes, what is your preference?
* must provide value
Normothermic
Hypothermic
We do not use any machine perfusion
19. What percentage of DCD hepatic grafts undergo machine perfusion after procurement?
* must provide value
Never < 10% < 50% ≥50% but not for all For all
20. All DCD hepatic grafts should undergo a machine perfusion approach before implantation
* must provide value
Strongly Agree Agree Neutral Disagree Strongly Disagree